Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every ≥ 3 Week Brentuximab Vedotin

NCT01703949 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01703949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01703949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every ≥ 3 Week Brentuximab Vedotin
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 20, 2013
Completion date
June 3, 2030
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent hodgkin lymphoma, recurrent non-hodgkin lymphoma, refractory hodgkin lymphoma, refractory non-hodgkin lymphoma